These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 27510947)

  • 1. Design-corrected variation by centre in mortality reduction in the ERSPC randomised prostate cancer screening trial.
    Hakama M; Moss SM; Stenman UH; Roobol MJ; Zappa M; Carlsson S; Randazzo M; Nelen V; Hugosson J
    J Med Screen; 2017 Jun; 24(2):98-103. PubMed ID: 27510947
    [TBL] [Abstract][Full Text] [Related]  

  • 2. What explains the differences between centres in the European screening trial? A simulation study.
    Nevalainen J; Stenman UH; Tammela TL; Roobol M; Carlsson S; Talala K; Schröder FH; Auvinen A
    Cancer Epidemiol; 2017 Feb; 46():14-19. PubMed ID: 27889661
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up.
    Schröder FH; Hugosson J; Roobol MJ; Tammela TL; Zappa M; Nelen V; Kwiatkowski M; Lujan M; Määttänen L; Lilja H; Denis LJ; Recker F; Paez A; Bangma CH; Carlsson S; Puliti D; Villers A; Rebillard X; Hakama M; Stenman UH; Kujala P; Taari K; Aus G; Huber A; van der Kwast TH; van Schaik RH; de Koning HJ; Moss SM; Auvinen A;
    Lancet; 2014 Dec; 384(9959):2027-35. PubMed ID: 25108889
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostate cancer mortality reduction by prostate-specific antigen-based screening adjusted for nonattendance and contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC).
    Roobol MJ; Kerkhof M; Schröder FH; Cuzick J; Sasieni P; Hakama M; Stenman UH; Ciatto S; Nelen V; Kwiatkowski M; Lujan M; Lilja H; Zappa M; Denis L; Recker F; Berenguer A; Ruutu M; Kujala P; Bangma CH; Aus G; Tammela TL; Villers A; Rebillard X; Moss SM; de Koning HJ; Hugosson J; Auvinen A
    Eur Urol; 2009 Oct; 56(4):584-91. PubMed ID: 19660851
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy versus effectiveness study design within the European screening trial for prostate cancer: consequences for cancer incidence, overall mortality and cancer-specific mortality.
    Zhu X; van Leeuwen PJ; Holmberg E; Bul M; Carlsson S; Schröder FH; Roobol MJ; Hugosson J
    J Med Screen; 2012 Sep; 19(3):133-40. PubMed ID: 23093731
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The efficacy of prostate-specific antigen screening: Impact of key components in the ERSPC and PLCO trials.
    de Koning HJ; Gulati R; Moss SM; Hugosson J; Pinsky PF; Berg CD; Auvinen A; Andriole GL; Roobol MJ; Crawford ED; Nelen V; Kwiatkowski M; Zappa M; Luján M; Villers A; de Carvalho TM; Feuer EJ; Tsodikov A; Mariotto AB; Heijnsdijk EAM; Etzioni R
    Cancer; 2018 Mar; 124(6):1197-1206. PubMed ID: 29211316
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of prostate cancer screening: a simulation study based on ERSPC data.
    Heijnsdijk EA; de Carvalho TM; Auvinen A; Zappa M; Nelen V; Kwiatkowski M; Villers A; Páez A; Moss SM; Tammela TL; Recker F; Denis L; Carlsson SV; Wever EM; Bangma CH; Schröder FH; Roobol MJ; Hugosson J; de Koning HJ
    J Natl Cancer Inst; 2015 Jan; 107(1):366. PubMed ID: 25505238
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Results and participation factors to the European Randomized study of Screening for Prostate Cancer (ERSPC) with Prostate Specific Antigen: French departments of Tarn and Hérault].
    Jegu J; Tretarre B; Grosclaude P; Rebillard X; Bataille V; Malavaud B; Iborra F; Salama G; Rischmann P; Villers A
    Prog Urol; 2009 Jul; 19(7):487-98. PubMed ID: 19559380
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate cancer mortality in the Finnish randomized screening trial.
    Kilpeläinen TP; Tammela TL; Malila N; Hakama M; Santti H; Määttänen L; Stenman UH; Kujala P; Auvinen A
    J Natl Cancer Inst; 2013 May; 105(10):719-25. PubMed ID: 23479454
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostate cancer mortality reduction by screening: power and time frame with complete enrollment in the European Randomised Screening for Prostate Cancer (ERSPC) trial.
    de Koning HJ; Liem MK; Baan CA; Boer R; Schröder FH; Alexander FE;
    Int J Cancer; 2002 Mar; 98(2):268-73. PubMed ID: 11857418
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Landmarks in prostate cancer screening.
    Schröder FH
    BJU Int; 2012 Oct; 110 Suppl 1():3-7. PubMed ID: 23046034
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Detailed Evaluation of the Effect of Prostate-specific Antigen-based Screening on Morbidity and Mortality of Prostate Cancer: 21-year Follow-up Results of the Rotterdam Section of the European Randomised Study of Screening for Prostate Cancer.
    de Vos II; Meertens A; Hogenhout R; Remmers S; Roobol MJ;
    Eur Urol; 2023 Oct; 84(4):426-434. PubMed ID: 37029074
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impacts of a population-based prostate cancer screening programme on excess total mortality rates in men with prostate cancer: a randomized controlled trial.
    van Leeuwen PJ; Kranse R; Hakulinen T; Hugosson J; Tammela TL; Ciatto S; Roobol MJ; Zappa M; de Koning HJ; Bangma CH; Moss SM; Auvinen A; Schröder FH
    J Med Screen; 2013 Mar; 20(1):33-38. PubMed ID: 28075228
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Finnish prostate cancer screening trial: analyses on the screening failures.
    Kilpeläinen TP; Tammela TL; Malila N; Hakama M; Santti H; Määttänen L; Stenman UH; Kujala P; Auvinen A
    Int J Cancer; 2015 May; 136(10):2437-43. PubMed ID: 25359457
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Screening for prostate cancer (PC)--an update on recent findings of the European Randomized Study of Screening for Prostate Cancer (ERSPC).
    Schröder FH
    Urol Oncol; 2008; 26(5):533-41. PubMed ID: 18774469
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Impact of Design and Performance in Prostate-Specific Antigen Screening: Differences Between ERSPC Centers.
    Heijnsdijk EAM; Adolfsson J; Auvinen A; Roobol MJ; Hugosson J; de Koning HJ
    Eur Urol; 2019 Sep; 76(3):276-279. PubMed ID: 31031050
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Number of Screening Rounds and Postscreening Prostate Cancer Incidence: Results from the Finnish Section of the European Randomized Study of Screening for Prostate Cancer Study.
    Pakarainen T; Raitanen J; Talala K; Taari K; Kujala P; Tammela TL; Auvinen A
    Eur Urol; 2016 Sep; 70(3):499-505. PubMed ID: 27210461
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Absolute Effect of Prostate Cancer Screening: Balance of Benefits and Harms by Center within the European Randomized Study of Prostate Cancer Screening.
    Auvinen A; Moss SM; Tammela TL; Taari K; Roobol MJ; Schröder FH; Bangma CH; Carlsson S; Aus G; Zappa M; Puliti D; Denis LJ; Nelen V; Kwiatkowski M; Randazzo M; Paez A; Lujan M; Hugosson J
    Clin Cancer Res; 2016 Jan; 22(1):243-9. PubMed ID: 26289069
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation between stage shift and differences in mortality in the European Randomised study of Screening for Prostate Cancer (ERSPC).
    Bokhorst LP; Zappa M; Carlsson SV; Kwiatkowski M; Denis L; Paez A; Hugosson J; Moss S; Auvinen A; Roobol MJ
    BJU Int; 2016 Nov; 118(5):677-680. PubMed ID: 27104278
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disease-specific survival of men with prostate cancer detected during the screening interval: results of the European randomized study of screening for prostate cancer-Rotterdam after 11 years of follow-up.
    Zhu X; van Leeuwen PJ; Bul M; Otto SJ; de Koning HJ; Bangma CH; Schröder FH; Roobol MJ
    Eur Urol; 2011 Aug; 60(2):330-6. PubMed ID: 21601352
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.